Hind.Bio Science

Why is Hindustan Bio Sciences Ltd falling/rising?

As of 11-Aug, Hindustan Bio Sciences Ltd's stock price is currently at 6.86, showing a short-term rise of 3.78%. However, it has been on a downward trend recently, with a total decline of -5.98% over the last three days and underperforming its sector, despite a year-to-date increase of +30.17%.

As of 11-Aug, Hindustan Bio Sciences Ltd's stock price is rising, currently at 6.86, with a change of 0.25 (3.78%) upward. Despite this increase today, the stock has been experiencing a downward trend, having fallen consecutively for the last three days, resulting in a total decline of -5.98% during this period. Additionally, the stock has underperformed its sector by -0.98%. <BR><BR>In terms of longer-term performance, the stock has shown a year-to-date increase of +30.17%, contrasting with a decline of -19.48% over the past year. However, it is trading below its moving averages across various time frames, indicating a bearish trend. <BR><BR>On a positive note, there has been a rise in investor participation, with delivery volume increasing by 52.19% against the 5-day average, suggesting some renewed interest in the stock despite its recent performance issues. Overall, while the stock is experiencing a short-term rise today, the broader context indicates ongoing challenges.

Which are the latest news on Hind.Bio Science?

When is the next results date for Hindustan Bio Sciences Ltd?

The next results date for Hindustan Bio Sciences Ltd is July 31, 2026.

The next results date for Hindustan Bio Sciences Ltd is scheduled for July 31, 2026.

How big is Hind.Bio Science?

As of 10th June, Hindustan Bio Sciences Ltd has a market capitalization of 8.00 Cr and reported Net Sales of 0.70 Cr with a Net Profit loss of 0.09 Cr over the latest four quarters. Shareholder's Funds are 0.90 Cr, and Total Assets are valued at 3.41 Cr.

As of 10th June, Hindustan Bio Sciences Ltd has a market capitalization of 8.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.70 Cr. However, it experienced a loss of 0.09 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds stood at 0.90 Cr, while Total Assets were valued at 3.41 Cr.

Who are in the management team of Hind.Bio Science?

The management team of Hind.Bio Science includes J.V.R. Mohan Raju (Chairman & Managing Director), B R Rao (Independent Director), J Uma (Director), K Rama Chandra Raju (Independent Director), and M Satyanarayana Raju (Independent Director).

The management team of Hind.Bio Science includes the following individuals:<BR><BR>1. **J.V.R. Mohan Raju** - Chairman & Managing Director<BR>2. **B R Rao** - Independent Director<BR>3. **J Uma** - Director<BR>4. **K Rama Chandra Raju** - Independent Director<BR>5. **M Satyanarayana Raju** - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Hind.Bio Science?

Hind.Bio Science's peers include Infronics Sys., Svam Software, First Fintec, CLIO Infotech, Nihar Info Glob., Virgo Global, Omni Ax's, and Pagaria Energy. In terms of performance, Hind.Bio Science has a 1-year return of -14.18%, better than Infronics Sys. (-50.92%) but worse than Nihar Info Glob. (21.58%).

Peers: The peers of Hind.Bio Science are Infronics Sys., Svam Software, First Fintec, CLIO Infotech, Nihar Info Glob., Virgo Global, Omni Ax's, and Pagaria Energy.<BR><BR>Quality Snapshot: Good management risk is observed at Infronics Sys., while Below Average management risk is found at Svam Software, First Fintec, Hind.Bio Science, Nihar Info Glob., Virgo Global, and the rest. Growth is rated as Good at CLIO Infotech, while Below Average growth is noted for Infronics Sys., Svam Software, First Fintec, Hind.Bio Science, Virgo Global, and the rest. Capital Structure is rated as Excellent at CLIO Infotech, while Good capital structure is observed at Infronics Sys., and Below Average capital structure is found at Svam Software, First Fintec, Hind.Bio Science, Nihar Info Glob., Virgo Global, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Nihar Info Glob. at 21.58%, while the lowest is Infronics Sys. at -50.92%. Hind.Bio Science's 1-year return is -14.18%, which is higher than Infronics Sys. but lower than Nihar Info Glob. Additionally, Infronics Sys., Svam Software, and First Fintec have negative six-month returns.

What does Hind.Bio Science do?

Hindustan Bio Sciences Ltd manufactures and sells pharmaceutical products and operates in the Software Products industry as a Micro Cap company. It was incorporated in 1991, with a market cap of INR 8 Cr and reported a net profit of 0 Cr for March 2026.

Overview:<BR>Hindustan Bio Sciences Ltd is engaged in the manufacturing and sale of pharmaceutical products and operates within the Software Products industry, categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated as a Public Limited Company on December 16, 1991, and was formerly known as Hindustan Softel Ltd. It commenced operations in 1992 and the latest quarterly results reported are for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 59.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 2.22<BR>Return on Equity: 14.00%<BR>Price-to-Book: 8.07<BR><BR>Contact Details:<BR>Address: H No 8-2-269/S PlotNo 31 RdNo2, Sagar Co-Op Hous Banjara Hills Hyderabad Telangana : 500034<BR>Tel: 91-40-23555161/23555181<BR>Email: pharma.hindustanbio@gmail.com<BR>Website: http://www.hindustanbiosciences.in

Are Hindustan Bio Sciences Ltd latest results good or bad?

Hindustan Bio Sciences Ltd's latest results are concerning, showing a net loss of ₹0.12 crores and zero net sales in Q4 FY26, indicating significant operational challenges and revenue volatility. The company's return on equity has also decreased, and its stock has underperformed compared to the market.

The latest results for Hindustan Bio Sciences Ltd are concerning. In the fourth quarter of FY26, the company reported a net loss of ₹0.12 crores, a significant decline from a profit of ₹0.08 crores in the previous quarter. Additionally, net sales plummeted to zero, marking a 100% decline quarter-on-quarter. This pattern of alternating between quarters with zero revenue raises serious questions about the company's operational viability.<BR><BR>The company's return on equity has also decreased, with the latest figure at 8.60%, down from 14.00%. Over the past year, the stock has underperformed, declining by 17.23%, compared to an 8.82% drop in the Sensex.<BR><BR>Overall, the financial performance indicates a troubling trend of revenue volatility and operational challenges, suggesting that the company's current situation is quite poor. The lack of consistent sales and the absence of institutional investor confidence further highlight the difficulties Hindustan Bio Sciences is facing.

Should I buy, sell or hold Hindustan Bio Sciences Ltd?

Is Hind.Bio Science overvalued or undervalued?

As of November 3, 2025, Hind.Bio Science is considered overvalued with a PE ratio of 54.70, significantly higher than its peers, and has underperformed the Sensex year-to-date, indicating a risky investment.

As of 3 November 2025, the valuation grade for Hind.Bio Science has moved from very expensive to risky. The company is currently considered overvalued. Key ratios include a PE ratio of 54.70, an EV to EBITDA of -10.08, and a PEG ratio of 0.82. <BR><BR>In comparison to its peers, Hind.Bio Science's PE ratio is significantly higher than Sun Pharma's 35.62 and Cipla's 22.44, indicating a premium valuation despite its negative earnings multiples. Additionally, while the stock has shown a strong return of 13.7% over the past week, it has underperformed the Sensex year-to-date, with a decline of 26.84%. Overall, these factors suggest that Hind.Bio Science is overvalued relative to its peers and financial metrics.

How has been the historical performance of Hind.Bio Science?

Hind.Bio Science has experienced fluctuating financial performance, with net sales declining from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, though profitability metrics show signs of recovery, particularly with an operating profit margin improving to 12.35% in Mar'25. Total liabilities and assets have also decreased during this period, while cash flow from operations has remained stagnant.

Answer:<BR>The historical performance of Hind.Bio Science shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Hind.Bio Science's net sales have seen a decline from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, with a peak of 1.94 Cr in Mar'20 and a slight recovery to 1.03 Cr in Mar'24 before falling again. Total operating income followed a similar trajectory, peaking at 3.56 Cr in Mar'19 and dropping to 0.81 Cr in Mar'25. The company has consistently reported no raw material costs, while the purchase of finished goods decreased from 2.92 Cr in Mar'19 to 0.49 Cr in Mar'25. Operating profit margins have fluctuated significantly, with a negative margin of -127.27% in Mar'22 improving to 12.35% in Mar'25. Profit after tax also showed volatility, moving from 0.11 Cr in Mar'19 to a loss of -0.94 Cr in Mar'21, before recovering to 0.10 Cr in Mar'25. The total liabilities have decreased from 5.55 Cr in Mar'20 to 3.41 Cr in Mar'25, while total assets have also declined from 5.55 Cr to 3.41 Cr in the same period. Cash flow from operating activities has remained stagnant, with no cash inflow or outflow recorded in the last few years. Overall, Hind.Bio Science has experienced significant fluctuations in its financial performance, with recent signs of recovery in profitability metrics.

What is the technical trend for Hind.Bio Science?

As of June 2, 2025, Hind.Bio Science shows a mildly bearish trend overall, with mixed signals from indicators suggesting some weekly strength but monthly weakness.

As of 2 June 2025, the technical trend for Hind.Bio Science has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD shows a mildly bullish signal, contrasting with the monthly MACD which is mildly bearish. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting some upward pressure. However, the KST indicates a mildly bullish trend weekly but is mildly bearish monthly. Overall, the mixed signals from the indicators suggest a mildly bearish stance with some strength in the weekly timeframe but overall weakness in the monthly perspective.

Who are the top shareholders of the Hind.Bio Science?

The top shareholder of Hind.Bio Science is promoter Venkata Rama Mohan Raju Jampana with 9.39%, followed by public shareholder Satyasai Kolli at 2.59%. Individual investors hold a substantial 84.02% of the shares, with no pledged promoter holdings or mutual fund/foreign institutional investor holdings.

The top shareholders of Hind.Bio Science include Venkata Rama Mohan Raju Jampana, who is the promoter with the highest holding at 9.39%. The highest public shareholder is Satyasai Kolli, holding 2.59%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 84.02% of the shares. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings.

Has Hind.Bio Science declared dividend?

No Dividend History Available